Prostate cancer is the third leading cause of death from cancer in men in Canada. The overall goal of our research is to provide an effective treatment option and improve the quality of life of prostate cancer patients. As a step towards this goal, we aim to translate our findings from cell-culture and toxicity studies in small animals (mice) to clinical studies in canine patients suffering from naturally acquired prostate cancer. Previous funding from RFD has enabled us to accomplished the cell-culture and toxities studies in mice. Our next step before any human trial is to complete clinical trials in canine dogs. Dogs serve as excellent translational model for prostate cancer research since they too develop spontaneous prostate cancer similar to that observed in men. In place of the typical radiotherapy options that can be highly invasive with long recovery time or side effects and require many hospital visits, this research envisions asingle injection of gold nanoparticles, coated with plant extract, into the prostate. Once in target, the nanoparticles deliver their therapeutic effects via the anti-cancer properties of the coating, radio-sensitization, imaging enhancement and the enhancement of externally delivered radiation dose. This multimodal-nanoparticle therapy potentially offers a reduced treatment burden while at the same time promising higher cure and lower complication rates.This combined and targeted treatment could change all aspects of managing prostate cancer.